-
12:27:20 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

INCY Stock News

05/26/22 6:00 AM
Nasdaq : INCY
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
Incyte today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 Congress. “We are committed to advancing science that can lead to solutions for patients with serious unmet medical needs, including those with cancer,” said Steven Stein, M.D., Chief Medical...
RHEA-AI
neutral
05/05/22 1:20 AM
Nasdaq : INCY
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
Incyte today announced the European Commission has approved Jakavi ® for the treatment of patients aged 12 years and older with acute or chronic GVHD who have inadequate response to corticosteroids or other systemic therapies. Ruxolitinib is marketed as Jakavi by Novartis in Europe and as Jakafi ® by Incyte in the United States. “With the approval of this...
RHEA-AI
positive
05/03/22 7:00 AM
Nasdaq : INCY
earnings
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Incyte today reports 2022 first quarter financial results, and provides a status update on the Company’ s clinical development portfolio. “Our double-digit growth in the first quarter reflects the strong performance of Jakafi ®– supported by the successful launch in chronic graft-versus-host disease in the United States– as well as continued growth for...
RHEA-AI
positive
04/22/22 9:40 AM
Nasdaq : INCY
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
Incyte today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency’ s has issued a positive opinion that recommends granting marketing authorization for capmatinib as a monotherapy for the treatment of adults with advanced non-small cell lung cancer harboring alterations leading to...
RHEA-AI
neutral